ChrysalisBioTherapeutics, Inc. is a privately held biopharmaceutical company developing regenerative drugs that mimic the body’s natural signals to activate endothelial progenitor cells and stem cells to stimulate tissue repair and restore normal tissue function. Chrysalis BioTherapeutics was incorporated in Delaware in 2012 to develop innovative peptide therapeutics to save lives and improve life’s quality.
Chrysalis’ lead drug candidate, TP508, was initially developed to accelerate healing of dermal and musculoskeletal injuries. TP508 proved to be especially effective in promoting healing of diabetic foot ulcers in early human clinical trials and is under development as a treatment for mass casualty injuries and unmet clinical needs. Chrysalis has demonstrated that TP508 mitigates effects of radiation exposure and is collaborating with US government agencies to develop TP508 as a nuclear countermeasure to increase survival and combat acute and delayed radiation syndromes. In addition, the company is developing TP508 to prevent damaging effects of trauma and radiation therapy on the brain and other tissues.
Loss of vascular endothelial cell function and decreased capacity of stem cells to replace damaged cells lead to age-related degenerative diseases in brain and other tissues. Trauma, ionizing radiation, and uncontrolled inflammation associated with chronic diseases are major causes of endothelial dysfunction and reduced stem cell activation in tissues throughout the body. These cellular effects result in loss of organ specific function and impaired healing in pediatric and adult populations. Thus, these cellular changes are at the root of many critical unmet medical needs.
Chrysalis is pioneering therapeutic use of TP508-related drugs that harness the body’s natural regenerative signals to protect and activate vascular endothelial cells and endogenous progenitor stem cells where they exist in brain and other tissues. Extensive research has shown that injection of TP508 safely restores endothelial function and activates normal stem cells to initiate tissue regeneration and overcome effects of trauma, ischemia, age-related degenerative disease, and radiation-induced tissue damage.
At Chrysalis, we are committed to develop and commercialize safe and effective drugs that utilize natural regenerative processes to save lives, improve quality of life, and provide therapeutic solutions for unmet medical needs.
Vision for the Future
Chrysalis aims to become the global leader in mitigating normal tissue damage induced by trauma, chronic degenerative disease, and ionizing radiation encountered during radiation therapy, accidental exposure, or a nuclear event. Use of TP508-related drugs will change the practice of medicine and provide outcome-changing solutions for treatment of neurocognitive decline caused by neurotrauma and neurodegenerative disease. TP508 treatment will save lives and improve life quality for adults and children and where failure to intervene may have life-long physical, behavioral or psychological effects.
Meet the Team
Darrell H Carney, PhDPresident & CEO
Darrell is an Adjunct Professor in the Department of Biochemistry and Molecular Biology at the University of Texas Medical Branch and founder of Chrysalis BioTherapeutics, Inc. Among his most important academic research achievements were: the identification of thrombin receptors on fibroblasts, endothelial cells, and progenitor stem cells that initiate tissue regeneration; and discovery of peptide drugs that could selectively activate these receptors to stimulate regenerative processes and restoration of endothelial function. As an academic scientist, he raised over 13 million dollars in NIH funding and has over 90 publications and 28 patents. Dr. Carney established his first tissue repair company in 1995, and sold the company after completion of a Phase 2 clinical trial in 2004 and re-acquired the rights to the same technology in 2012.
Clarice I MotterInterim CFO
Clarice is a licensed CPA with more than 20 years’ experience as an accountant and administrative professional. Her experience in public and privately owned companies includes mergers, acquisitions, and public offerings. She has recently worked with a number of early-stage companies bringing them into fiscal compliance and playing a key role in raising funding through public and private sources.
Laurie E Sower, PhDExecutive Vice President
Laurie has over 15 years experience in directing laboratory operations, quality data system management, and prior experience with TP508. Her prior research at the University of Texas Medical Branch demonstrated a unique TP508 (Chrysalin) receptor-mediated signaling cascade involved in tissue repair. Laurie has been the Principle Investigator (PI/PD) on several of the company’s SBIR grants and contracts and directs all Non-Clinical Regulated Studies for Chrysalis BioTherapeutics.
Gerald M Fuller, PhDVice President of Research
Gerald is a Professor Emeritus, Department of Cell Biology at the University of Alabama Medical School with expertise in molecular biology, progenitor cell biology, and vascular biology. Gerry was one of the first scientists to discover IL-6 and its involvement in stimulating hepatocytes. Gerry has been a scientific consultant with Chrysalis BioTechnology, OrthoLogic, and Merck and currently directs a team of scientists working to better understand the molecular mechanisms by which TP508 targets progenitor cells to protect and regenerate tissues.
Changing Lives Through Innovation